pasitheaclinics.com (KTTA): Forward Price-to-Revenue Multiple
Pasithea Therapeutics focuses on developing RNA therapies to combat mental disorders. The GURU.Markets service provides this chart, where the forward P/S indicator demonstrates volatility, while the 39.40 mark indicates the current valuation level. Geopolitics are hindering international trials and reagent procurement, while a lack of profitability and reliance on venture capital investments deprive the company of pricing power.
KTTA (Pasithea Therapeutics Corp): analytical breakdowns and indicator data
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Pasithea Therapeutics|KTTA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Pasithea Therapeutics|KTTA - Aggregate Debt Obligations|Debts to Book Capitalization Pasithea Therapeutics|KTTA - Company Long-Term Debts|Company Short-Term Debt Pasithea Therapeutics|Quick Ratio pasitheaclinics.com
- net income and valuation multiples indicators:
KTTA - Company Net Income|Future Profit Pasithea Therapeutics|KTTA - P/E Multiple|Projected Price to Earnings Pasithea Therapeutics Corp.|KTTA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Pasithea|KTTA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Pasithea Therapeutics|KTTA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months pasitheaclinics.com|KTTA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Pasithea Therapeutics
- issuer revenue and sales details:
Summary company analysis:Pasithea Therapeutics KTTA
Forward P/S determines the market value of a business relative to expected sales volume, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S trend, an investor can see the speculative nature of the valuation of Pasithea Therapeutics (KTTA), whose capitalization is based on venture expectations from neuropsychiatric clinical trials rather than the actual presence of stable revenue.
Competitors of Pasithea Therapeutics
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cyclerion.com CYCN|Forward P/S Multiple PTIX|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
